Evidence map›Paper›PMID 20117930›Full record

ArticleBioorganic & medicinal chemistry letters2010

Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs.

John E Coughlin, Seetharamaiyer Padmanabhan, Guangrong Zhang, Cassandra J Kirk, Chandrika P Govardhan, Brent E Korba, Kathleen O'Loughlin, Carol E Green, Jon Mirsalis, John D Morrey and 1 more

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

John E CoughlinSpring Bank Pharmaceuticals Inc., Milford, MA, United States.
Seetharamaiyer Padmanabhan
Guangrong Zhang
Cassandra J Kirk
Chandrika P Govardhan
Brent E Korba
Kathleen O'Loughlin
Carol E Green
Jon Mirsalis
John D Morrey
Radhakrishnan P Iyer

Funding

THE DINUCLEOTIDE SB-9000 A NOVEL ANTI-HBV AGENTU01AI058270 · NIAID · SPRING BANK TECHNOLOGIES, INC. · PI IYER, RADHAKRISHNAN P · 2003 to 2007
$2.4M
Cellular immunity to P. aeruginosa candidate vaccinesK08AI050036 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI PRIEBE, GREGORY P · 2001 to 2005
$621k
NIAID NIH HHS N01 AI050036NIAID NIH HHS N01 AI060011NIAID NIH HHS N01-AI-50036NIAID NIH HHS U01 AI058270NIAID NIH HHS UO1-AI-058270
6 · The paper itself

Abstract

The acyloxyalkyl derivatives of a model anti-HBV dinucleotide were synthesized and evaluated as orally bioavailable prodrugs. Our studies have led to the identification of the first orally bioavailable dinucleotide prodrugs for further therapeutic development against the hepatitis B virus (HBV).

Indexed as

Administration, OralAnimalsAntiviral AgentsCell LineFemaleHepatitis BHepatitis B virusHumansMaleMiceMice, TransgenicMutationNucleotidesProdrugsRatsRats, Sprague-DawleyAntiviral AgentsNucleotidesProdrugs

Identifiers

PMID20117930
PMCPMC2826611

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.